OncRef

Clinical Trial: NCT04736706

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 3

Lead Sponsor:Merck Sharp & Dohme LLC
Information Provided By:Merck Sharp & Dohme LLC
Last Update Posted:2026-11-06

Study Overview

Brief Summary

The goal of this study is to evaluate the efficacy and safety of pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib as first-line treatment in participants with advanced clear cell renal cell carcinoma (ccRCC).

The primary hypotheses are (1) pembrolizumab plus belzutifan plus lenvatinib is superior to pembrolizumab plus lenvatinib with respect to progression-free survival (PFS) and overall survival (OS), in advanced ccRCC participants; and (2) pembrolizumab/quavonlimab plus lenvatinib is superior to pembrolizumab plus lenvatinib with respect to PFS and OS, in advanced ccRCC participants.

Official Title

An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or MK-1308A in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, as First-Line Treatment in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

Conditions

Carcinoma, Renal Cell

Intervention / Treatment

  • Biological: Pembrolizumab
  • Drug: Belzutifan
  • Biological: Pembrolizumab/Quavonlimab
  • Drug: Lenvatinib

Other Study ID Numbers

  • 6482-012
  • MK-6482-012
  • jRCT2031210435
  • PHRR210911-003887
  • 2022-502122-41-00
  • U1111-1283-3681
  • 2020-002216-52

Start Date (Actual)

2021-04-14

Primary Completion Date (Actual)

2026-02-04

Study Completion Date (Estimated)

2027-04-22

Enrollment (Actual)

1688

Study Type

Interventional

Phase

Phase 3